№ lp_1_2_36718
File format: docx Character count: 8054 File size: 57 KB
This document provides risk management guidelines for ophthalmologists using triamcinolone acetonide (KenalogTM or TriesenceTM) in intraocular injections, including off-label usage, FDA regulations, patient monitoring, and complications management.
Year: 2020
Region / city: USA
Theme: Ophthalmology, Medical Risk Management
Document type: Risk Management Recommendations
Organization: OMIC
Author: Anne M. Menke, RN, PhD
Target audience: Ophthalmologists
Effective period: Ongoing
Approval date: 8/4/20
Date of changes: None specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Section 790.6570 Neomycin Sulfate; Triamcinolone Acetonide (Repealed)
Year: 1992
Region / City: Illinois
Topic: Pharmaceutical Regulations
Document Type: Legal Regulation
Organization: State of Illinois
Author: Illinois General Assembly
Target Audience: Legal professionals, regulatory bodies
Effective Date: August 10, 1992
Date of Repeal: Not specified
Context Description: Legal document regarding the repeal of regulations for neomycin sulfate and triamcinolone acetonide in Illinois.
Topics: KenalogTM TriesenceTM Triamcinolone